U.S. Markets closed

EMA recommends extended indications for Glaxo's Cervarix

The Committee for Medicinal Products for Human Use adopted a positive opinion recommending a variation to the terms of the marketing authorization for the medicinal product Cervarix from GlaxoSmithKline Biologicals. The CHMP adopted an extension to the therapeutic indication for the prevention of premalignant genital, cervical, vulvar and vaginal, lesions causally related to certain oncogenic Human Papillomavirus types.